Stay updated with breaking news from Michael Lampe. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
CAMBRIDGE, Mass., April 06, 2023 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting... | April 6, 2023
CAMBRIDGE, Mass., April 06, 2023 -- Foghorn® Therapeutics Inc. , a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting abnormal... | June 20, 2023
09.08.2022 - - FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues to progress per protocol; working to resolve partial clinical hold in AML and MDS - On track to report initial Phase 1 clinical data for FHD-609 in synovial ...
Foghorn Therapeutics Provides Second Quarter 2022 Financial and Corporate Update -FHD-286 dose escalation Phase 1 study in metastatic uveal melanoma continues... | August 9, 2022
DCVC and Magnetic Ventures co-led a $25 million seed financing, with participation from Khosla Ventures, OMERS Ventures, and firstminute Capital, among others Relation Therapeutics, the pioneer of